The skin microbiome: the overlooked axis in modern dermatology
Narrative editorial concludes that the cutaneous microbiome is relevant to skin disease, but current associations are predominantly correlational and insufficient to guide clinical decisions.
| Population | Patients with common dermatoses (atopic dermatitis, acne vulgaris, psoriasis, chronic wounds) and dermatology practitioners |
|---|---|
| Intervention | Integration of the skin microbiome (assessment, microbiome-directed therapies, antimicrobial stewardship) into dermatologic practice |
| Comparator | Conventional barrier- and immunology-centered approaches |
| Outcome | S. aureus association with atopic dermatitis; C. acnes phylotypes and acne severity; Microbial alterations in psoriasis; Biofilms and delayed healing in chronic wounds; Efficacy of topical probiotics in dermatoses; Bacteriophage therapy targeting S. aureus; Antimicrobial stewardship in chronic dermatoses |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| S. aureus association with atopic dermatitis | no quantitative effect size reported | — | Low | — | |
| C. acnes phylotypes and acne severity | no quantitative effect size reported | — | Low | — | |
| Microbial alterations in psoriasis | no quantitative effect size reported; inconsistent across cohorts | — | Very low | — | |
| Biofilms and delayed healing in chronic wounds | no quantitative effect size reported | — | Low | — | |
| Efficacy of topical probiotics in dermatoses | no quantitative effect size reported; derived from small or mechanistic studies | — | Very low | — | |
| Bacteriophage therapy targeting S. aureus | investigational; in the quantitative effect size reported | — | Very low | — | |
| Antimicrobial stewardship in chronic dermatoses | no quantitative effect size reported; proposed as feasible entry point only | — | Very low | — |
Context
Dermatology has built strong evidence on barrier dysfunction and immune dysregulation, but rarely incorporates microbial metrics into diagnostic or therapeutic pathways. Microbial signatures have been identified in atopic dermatitis, acne, psoriasis, and chronic wounds, yet causal directionality remains undefined. Lack of standardization in sequencing and absence of validated diagnostic thresholds limit clinical application.
What the study showed
The editorial synthesizes that S. aureus increases during atopic dermatitis flares with reduced microbial diversity, but causality is not established. In acne, disease severity correlates with specific C. acnes phylotypes rather than total bacterial abundance. In psoriasis, data on Malassezia and other bacteria are inconsistent across cohorts. Microbiome-directed therapies (topical probiotics, bacteriophages, microbial transplantation) are derived mostly from small or mechanistic studies without generalizability.
How it was done
Narrative editorial published in Annals of Medicine & Surgery (2026), without systematic review protocol, structured search, or formal risk-of-bias assessment. Number of included studies and explicit selection criteria are not reported. Relies on selectively cited literature.
Effect magnitude
No quantitative effect size was reported. All associations are described qualitatively, without 95% CI, RR, OR, or SMD.
Risk of bias
Narrative editorial design without systematic methodology — AMSTAR-2 not applicable; RoB 2 and ROBINS-I not applied to primary sources. Literature selection is potentially biased. Absence of quantitative data prevents assessment of magnitude or direction of effect for any specific outcome. Causal conclusions are explicitly avoided by the authors themselves.
What this study does NOT prove
This editorial does not prove causality between dysbiosis and any dermatological disease. It does not support adoption of any microbiome-directed therapy as an intervention of established efficacy.
In clinical practice
Antimicrobial stewardship is the most immediately applicable recommendation: avoid unnecessary broad-spectrum antibiotics in chronic dermatoses. Consider the impact of topical antiseptics, emollients, and corticosteroids on resident microbiota during long-term use. Microbiome-directed therapies should not be adopted in routine practice without rigorous clinical trials.
Limitations
Narrative editorial design without systematic methodology — AMSTAR-2 not applicable; RoB 2 and ROBINS-I not applied to primary sources. Literature selection is potentially biased. Absence of quantitative data prevents assessment of magnitude or direction of effect for any specific outcome. Causal conclusions are explicitly avoided by the authors themselves.
What is still missing
Randomized clinical trials with standardized outcomes and adequate follow-up for microbiome-directed therapies in specific dermatoses. Longitudinal studies with functional metagenomics to distinguish causality from association.
Technical appendix
Version history
- 1.0 · 2026-08-02 — Auto-generated under Evidence Standard v1.0